Catalent Stock: Is CTLT Outperforming the Healthcare Sector?

Based in Somerset, New Jersey, Catalent, Inc. (CTLT) develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products. Valued at a market cap of $10.8 billion, the company serves biotechnology, pharmaceutical, consumer health companies, animal health and medical device companies, and cosmetics industries as well. 

Companies valued at $10 billion or more are generally described as “large-cap” stocks, and Catalent fits right into that category. The company is a global leader in drug development and delivery. It helps accelerate over 1,000 partner programs and launch over 150 new products yearly with its over 18,000 workforce, including more than 3,000 scientists and technicians.